

## Survey for Therapeutic Drugs

EQA Provider: ESfEQA GmbH  
Heidelberg  
Survey Coordinator: Dr. D. Groche

### Instructions for Use

#### Notes:

The usual precautions in the laboratory for potentially hazardous material apply for these samples. Human source material used to produce these samples were tested and found to be non-reactive for HBsAg, anti-HIV 1/2 and anti-HCV.

Various tasks of the proficiency testing scheme may occasionally be given over to qualified subcontractors. However, ESfEQA is responsible to the participants for the subcontractor's work.

Results from sample analysis may only be disclosed to colleagues from other laboratories after the testing period has been concluded.

By registering for and participating in this EQA participants agree to accept the general terms and conditions of ESfEQA GmbH. These can be retrieved online at [www.esfeca.eu](http://www.esfeca.eu)

### 1. Intended Use

The samples are intended for use as quantitative control material for External Quality Assessment (EQA) in medical laboratories for the following analytes:

Amikacin, Carbamazepine, Chinidine, Digoxin, Ethosuximide, Gentamicin, Lidocain, Paracetamol, Phenobarbital, Phenytoin, Primidone, Salicylate, Theophylline, Valproic Acid, Vancomycin

### 2. Product Description

The controls are lyophilized material based on human serum.

### 3. Storage and Stability

The samples should be stored upright at 2-8 °C. They are stable at least until the deadline for data submission as indicated below.

After reconstitution, the samples are stable in tightly recapped vials for:

- 2 days at 2-8 °C

### 4. Sample Preparation and Analysis

Carefully open the vial without any loss of material. Add 3 mL of distilled or deionized water to the lyophilisate and set aside for 10 min. Swirl gently and invert the vial several times until the lyophilisate is completely dissolved. Use after further 20 minutes.

The samples should be treated the same way as patient samples and analyzed in accordance with the instructions of the instrument and reagent manufacturer.

### 5. Dates and Submission of Test Results

Testing Periods: Please refer to the sample labels. Results can be submitted anytime within the testing period indicated on the sample labels.

Please submit your results electronically to ESfEQA at <https://teqa.esfeca.eu>.

Contact your local distributor of ESfEQA programs or ESfEQA directly if you need assistance with registration in TEQA. Alternatively, though not preferred, use the result form provided on the ESfEQA website. In both cases indicate the instrument and method used for the analysis of the samples.

Quantitative results are generally reported with a value and a unit. The participant determines the number of digits for reporting. Results specified as e.g. ' $<$  below measuring range' or ' $< 0.02$ ' are not valid. If the analyzer system displays such results, they shall be interpreted as following: For results within the measuring range and below the Limit of Quantification (LoQ) the obtained value should be reported. For results below the Limit of Detection (LoD), this limit should be reported. For samples that have analyte concentrations above the test range, the sample can be diluted (if recommended for particular applications) or the upper test range limit can be reported as result.

### 6. Deadline for Data Submission

The deadlines for submitting results are indicated on the sample labels (time zone GMT +1).

### 7. Reports and Certificates

The data will be evaluated by ESfEQA. The individual laboratory reports and certificates can be retrieved online at <https://teqa.esfeca.eu>.